Metagenomic Sequencing Global Market Report 2024

The metagenomic sequencing market size has grown rapidly in recent years. It will grow from $1.82 billion in 2023 to $2.13 billion in 2024 at a compound annual growth rate (CAGR) of 16.9%. The growth in the historic period can be attributed to the increasing involvement of governments, a growing number of metagenome sequencing research projects, the expanding application of metagenomics in genomics and diagnostics research, the availability of research funding, and the development of Next-Generation Sequencing (NGS) data analysis tools.

The metagenomic sequencing market size is expected to see rapid growth in the next few years. It will grow to $4.02 billion in 2028 at a compound annual growth rate (CAGR) of 17.2%. The growth in the forecast period can be attributed to decreasing computational costs, a growing focus on discovering novel biomolecules of interest, increasing adoption of high-throughput sequencing technologies, demand for personalized medicine and disease diagnosis, and a surge in the prevalence of infectious diseases. Major trends in this period include innovative technologies, the utilization of advanced genomic technologies in metagenomics, augmented R&D funding, advancements in sequencing technology, and the use of big data for NGS data analysis.

The increase in infectious diseases is expected to fuel the growth of the metagenomic sequencing market. These diseases, caused by pathogenic microorganisms such as bacteria, viruses, parasites, or fungi, can spread from person to person directly or indirectly. Conditions that compromise the immune system, such as HIV/AIDS, cancer treatments, and autoimmune disorders, can heighten susceptibility to infectious diseases. Metagenomic sequencing is a robust method for studying infectious diseases, offering insights into pathogen diversity, transmission dynamics, antimicrobial resistance, and outbreak surveillance. For example, as per UNAIDS in July 2023, global HIV cases surpassed 39 million, up 3.17% from 2020, with nearly 1.3 million new infections in 2022. Additionally, the Centers for Disease Control and Prevention reported a 5.9% rise in tuberculosis cases in the US from 2021 to 2022. This surge in infectious diseases is propelling growth in the metagenomic sequencing market.

Key players in the metagenomic sequencing market are concentrating on enhancing sequencing services to improve accuracy, throughput, and cost-effectiveness. Sequencing services involve advanced genomic technologies enabling the sequencing of longer DNA fragments, providing a more detailed view of genetic structures compared to traditional short-read methods. For instance, Clinical Microbiomics A/S introduced advanced long-read sequencing services in April 2024, including 16S, ITS, 18S rRNA, custom gene sequencing, and comprehensive genomics and metagenomics. These services offer unparalleled resolution and quality in microbial analysis, facilitating detailed insights into microbial communities and the creation of high-quality metagenome-assembled genomes.

In January 2022, Illumina Inc. acquired IDbyDNA to bolster its infectious disease diagnostics and microbial genomics capabilities. This acquisition integrates IDbyDNA's expertise in metagenomic sequencing and bioinformatics with Illumina's portfolio of sequencing technologies and analytical solutions, enhancing their position in pathogen surveillance and infectious illness testing.

Major companies operating in the metagenomic sequencing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Merck Co. & KGaA, Eurofins Scientific SE, PerkinElmer Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Beijing Genomics Institute Group, Azenta Inc., Promega Corporation, Novogene Co. Ltd., Oxford Nanopore Technologies plc, Zymo Research Corporation, Metagenomi Inc., Psamogen Inc., IntegraGen SA, Karius Inc., DNAStar Inc., Macrogen Inc., Takara Bio Inc., Arc Bio LLC, Microsynth AG, Computomics GmbH, COSMOSID Inc., Phase Genomics Inc., Era7 Bioinformatics GmbH.

North America was the largest region in the metagenomic sequencing market in 2023. Asia-Pacific is expected to be the fastest growing region in the market. The regions covered in the metagenomic sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the metagenomic sequencing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Metagenomic sequencing is a technique used to analyze the genetic material from an entire community of microorganisms in a specific environment without culturing individual species. This method involves extracting DNA directly from environmental samples, such as soil, water, or the human gut, and then sequencing it using high-throughput sequencing technologies.

The main products and services in the metagenomic sequencing market include reagents and consumables, instruments, sequencing services, and analysis and data interpretation solutions. Reagents and consumables encompass the chemical substances, kits, and disposable items used in laboratory experiments and procedures. The various technologies include 16S rRNA sequencing, shotgun metagenomic sequencing, whole-genome sequencing and de novo assembly, and metatranscriptomics. These technologies are used in various applications such as clinical diagnostics, environmental remediation, gut microbe characterization, drug discovery, biofuel production, agriculture, and other fields.

The metagenomic sequencing market research report is one of a series of new reports that provides metagenomic sequencing market statistics, including metagenomic sequencing industry global market size, regional shares, competitors with a metagenomic sequencing market share, detailed metagenomic sequencing market segments, market trends, and opportunities, and any further data you may need to thrive in the metagenomic sequencing industry. This metagenomic sequencing research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The metagenomic sequencing market includes revenues earned by entities by providing services such as sample preparation, sequencing, metagenomic profiling, and data analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The metagenomic sequencing market also includes sales of sequencing platforms, bioinformatics software, DNA extraction kits, and sequencing reagents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.